To evaluate the efficiency of non-BC or BC gene targeting in long-term engrafting HSPCs, bone marrow MNCs were sorted by flow cytometry into lineages CD19+ and CD33+, as well as the multipotent HSPC (CD19−CD33−CD10−CD34+) populations. This evidence concerns the gene CD33 and breast cancer.